Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biofrontera Inc. (BFRI : NSDQ)

• Company Description    Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA. Number of Employees: 69

• Price / Volume Information    Yesterday's Closing Price: $2.80 Daily Weekly Monthly 20 Day Moving Average: 474,387 shares Shares Outstanding: 17.10 (millions) Market Capitalization: $47.89 (millions) Beta: 52 Week High: $14.63 52 Week Low: $2.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.32% -17.01% 12 Week -5.41% 4.00% Year To Date -62.77% -54.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 120 PRESIDENTIAL WAY SUITE 330 - WOBURN,MA 01801 USA ph: 781-245-1325 fax: - us-ir@biofrontera.com http://www.biofrontera.us.com

• General Corporate Information    Officers Erica Monaco - Chief Executive Officer Hermann Lubbert - Chairman of the Board of Directors John J. Borer - Director Loretta M. Wedge - Director Kevin D. Weber - Director Peer Information Biofrontera Inc. (CORR.) Biofrontera Inc. (RSPI) Biofrontera Inc. (CGXP) Biofrontera Inc. (BGEN) Biofrontera Inc. (GTBP) Biofrontera Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077D100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 17.10 Most Recent Split Date: (:1) Beta: Market Capitalization: $47.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 80.95% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 6.36% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 3.44 12/31/21 - 3.36 09/30/21 - 0.90 Quick Ratio 03/31/22 - - 12/31/21 - 3.03 09/30/21 - 0.42 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -156.25 09/30/21 - - Book Value 03/31/22 - 1.02 12/31/21 - 0.66 09/30/21 - -1.50 Inventory Turnover 03/31/22 - - 12/31/21 - 2.57 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©